ClinicalTrials.gg
RecruitingNCT06796595REGENUpdated Jan 28, 2025

Perioperative Medical Program to Optimize Nerve Regeneration After Robot-assisted Laparoscopic Neurolyses of Pudendal and/or Inferior Cluneal Nerves for Chronic Neuralgias: Results After 1-year Follow-up

An observational study in Pudendal Neuralgia and Neuralgia, sponsored by UBOSGA. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by UBOSGA · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

Pudendal and inferior cluneal neuralgias are responsible for chronic pelvicperineal pain. These two neuralgias are associated in approximately 25% of cases. In the event of failure of first-line multimodal medical treatment, a mini-invasive robot-assisted laparoscopic decompression can be proposed. These surgeries carry the risk of neurapraxia, leading to a temporary increase in neuropathic pain and numbness in the nerve sensitive area, a motoric or neurovegetative disturbance (pudendal).

02

Conditions studied

  • Pudendal Neuralgia
  • Neuralgia
03

In context

Pudendal Neuralgia

20 studies on the registry are indexed under Pudendal Neuralgia; 7 are open to participants now.

Browse Pudendal Neuralgia studies →

Lead sponsor

UBOSGA is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This cohort study is a pilot study to evaluate the 1-year effectiveness of a perioperative medical program on the characteristics of neuropathic pain related to postoperative neurapraxia, following robot-assisted laparoscopic neurolyses of the pudendal and inferior cluneal nerves

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years old
  • Patients presenting a pudendal and/or inferior cluneal neuralgias with failure of the medical treatment
  • Patient having given consent after reading the information note

Exclusion criteria

Exclusion Criteria:

  • Inoperable patients ( to anesthesia or surgery) surgical contraindications)
  • Person deprived of liberty or under guardianship
  • Person under court protection
  • Pregnant or breast-feeding woman
  • Minors
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluate the 1-year effectiveness of a perioperative medical program on the characteristics of neuropathic pain related to postoperative neurapraxia, following robot-assisted laparoscopic neurolyses of the pudendal and inferior cluneal nerves

    Numeric pain scale (0 "no pain" to 10 "maximal pain")

    Time frame: Pré-operatively, and then post-operatively : every day the first month, then once a week until the 4th month then at 1 year year after surgery

Secondary outcomes

  1. Report all complications during the follow-up

    Complications are evaluated with Clavien-Dindo classification (Grade I to V(death))

    Time frame: 2 days, 4 months, 1 year after surgery

  2. Evaluate the effect of the surgical technique on anxiety

    Anxiety is evaluated with STAI (State Trait Anxiety Inventory-form) (anxious personality since STAI score 51 for women, and score 61 for men)

    Time frame: Pré-operatively, 2 days, 4 months, 1 year after surgery

  3. Evaluate the effect of the surgical technique on depression

    Depression is evaluated with Beck inventory (mild to moderate depression since score 10, moderate depression since score 19, severe depression since score 30)

    Time frame: Pré-operatively, 2 days, 4 months, 1 year after surgery

  4. Evaluate the effect of the surgical technique on post-traumatic stress syndrome

    Post-traumatic stress syndrome is evaluated with PCL-5 (post-traumatic stress disorder checklist with a PTSD since score 38

    Time frame: Pré-operatively, 2 days, 4 months, 1 year after surgery

  5. Evaluate the impact on quality of life

    Quality of life is evaluated with SF-36 (36-item Short Form Health Survey)

    Time frame: Pré-operatively, 2 days, 4 months, 1 year after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Jan 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 28, 2025
StartEst.
Jan 23, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06796595
Lead sponsor
UBOSGA
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Jan 23, 2025 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jan 28, 2025

Study contacts

Olivier Celhay, M.D
Contact
celhay.ubsg33@gmail.com
+33(0)5 56 11 61 44
Alexandra Dupire
Contact
arc.ubosga@gmail.com
+33(0)6 07 87 05 56

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion